Northern Trust Corp Has $18.40 Million Stock Holdings in Dynavax Technologies Corporation $DVAX

Northern Trust Corp trimmed its holdings in shares of Dynavax Technologies Corporation (NASDAQ:DVAX - Free Report) by 2.7% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,418,435 shares of the biopharmaceutical company's stock after selling 39,413 shares during the quarter. Northern Trust Corp owned about 1.18% of Dynavax Technologies worth $18,397,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of the business. Deep Track Capital LP increased its position in Dynavax Technologies by 42.0% during the fourth quarter. Deep Track Capital LP now owns 17,791,486 shares of the biopharmaceutical company's stock worth $227,197,000 after acquiring an additional 5,265,000 shares during the period. Deerfield Management Company L.P. Series C increased its position in Dynavax Technologies by 23,990.1% during the fourth quarter. Deerfield Management Company L.P. Series C now owns 5,193,823 shares of the biopharmaceutical company's stock worth $66,325,000 after acquiring an additional 5,172,263 shares during the period. Blair William & Co. IL increased its position in Dynavax Technologies by 0.5% during the first quarter. Blair William & Co. IL now owns 2,272,707 shares of the biopharmaceutical company's stock worth $29,477,000 after acquiring an additional 11,030 shares during the period. Invesco Ltd. increased its position in Dynavax Technologies by 33.8% during the first quarter. Invesco Ltd. now owns 2,207,631 shares of the biopharmaceutical company's stock worth $28,633,000 after acquiring an additional 558,046 shares during the period. Finally, D. E. Shaw & Co. Inc. increased its holdings in Dynavax Technologies by 34.0% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 1,918,340 shares of the biopharmaceutical company's stock valued at $24,497,000 after buying an additional 486,981 shares during the period. 96.96% of the stock is owned by institutional investors.

Dynavax Technologies Price Performance

Shares of Dynavax Technologies stock traded up $0.08 during midday trading on Friday, hitting $10.06. 1,421,965 shares of the company traded hands, compared to its average volume of 1,905,858. The stock has a market cap of $1.18 billion, a price-to-earnings ratio of -21.87 and a beta of 1.24. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.01 and a current ratio of 6.65. The firm's fifty day moving average price is $10.63 and its 200-day moving average price is $11.21. Dynavax Technologies Corporation has a 12 month low of $9.22 and a 12 month high of $14.63.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $0.02. The company had revenue of $95.44 million for the quarter, compared to analyst estimates of $87.55 million. Dynavax Technologies had a negative net margin of 16.67% and a positive return on equity of 5.10%. As a group, sell-side analysts forecast that Dynavax Technologies Corporation will post 0.32 earnings per share for the current year.

Insider Activity

In other Dynavax Technologies news, Director Scott Dunseth Myers bought 3,800 shares of the business's stock in a transaction that occurred on Friday, August 22nd. The shares were acquired at an average cost of $10.82 per share, for a total transaction of $41,116.00. Following the transaction, the director directly owned 35,004 shares in the company, valued at approximately $378,743.28. This represents a 12.18% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 2.98% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have commented on DVAX. Wall Street Zen raised shares of Dynavax Technologies from a "hold" rating to a "buy" rating in a report on Saturday, August 9th. JMP Securities reissued a "market outperform" rating and issued a $32.00 target price on shares of Dynavax Technologies in a report on Friday, August 22nd. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Dynavax Technologies has an average rating of "Moderate Buy" and a consensus target price of $24.33.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.